Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Mak, Anselm ^a   Cheung, Mike Wl ^a   Ho, Roger Chun Man ^b   Cheak, Alicia Ai Cia ^a   Lau, Chak Sing ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BAYES THEOREM; BONE ATROPHY; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFECT; DRUG USE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INCIDENCE; META ANALYSIS; OBSERVATIONAL STUDY; PATIENT SAFETY; POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ATRIAL FIBRILLATION; BAYES THEOREM; DIPHOSPHONATES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 70350434353     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-113     Document Type: Article

References (40)

1. Alendronate for the treatment of osteoporosis in men. WP Olszynski KS Davison, Expert Opin Pharmacother 2008 9 491 498 10.1517/14656566.9.3.491 18220499
2. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. GA Wells A Cranney J Peterson M Boucher B Shea V Robinson D Coyle P Tugwell, Cochrane Database Syst Rev 2008 1 D001155 18253985
3. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. G Wells A Cranney J Peterson M Boucher B Shea V Robinson D Coyle P Tugwell, Cochrane Database Syst Rev 2008 1 D004523 18254053
4. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. E Canalis G Mazziotti A Giustina JP Bilezikian, Osteoporos Int 2007 18 1319 1328 10.1007/s00198-007-0394-0 17566815
5. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: A consensus document of the Belgian Bone Club. JP Devogelaer S Goemaere S Boonen JJ Body JM Kaufman JY Reginster S Rozenberg Y Boutsen, Osteoporos Int 2006 17 8 19 10.1007/s00198-005-2032-z 16217586
6. Alendronate for the treatment of osteoporosis in men. E Orwoll M Ettinger S Weiss P Miller D Kendler J Graham S Adami K Weber R Lorenc P Pietschmann K Vandormael A Lombardi, N Engl J Med 2000 343 604 610 10.1056/NEJM200008313430902 10979796
7. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. JD Adachi KG Saag PD Delmas UA Liberman RD Emkey E Seeman NE Lane JM Kaufman PEE Poubelle F Hawkins R Correa-Rotter CJ Menkes JA Rodriguez-Portales TJ Schnitzer JA Block J Wing HH McLlwain R Westhovens J Brown JA Melo-Gomes BL Gruber MJ Yanover MOR Leite KG Siminoski MC Nevitt JT Sharp MP Malice T Dumortier M Czachur W Carofano, et al. Arthritis Rheum 2001 44 202 211 10.1002/1529-0131(200101)44:1<202::AID-ANR273.0.CO;2-W 11212161
8. Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. JD Ringe H Faber P Farahmand A Dorst, Rheumatol Int 2006 26 427 431 10.1007/s00296-005-0004-4 16001181
9. Assessment of mortality in patients enrolled in a risedronate clinical trial program: A retrospective cohort study. M Steinbuch RB D'Agostino JS Mandel E Gabrielson MR McClung A Stemhagen A Hofman, Regul Toxicol Pharmacol 2002 35 320 326 10.1006/rtph.2002.1550 12202047
10. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: A randomized double-blind placebo-controlled trial. CC Mok KH Tong CH To YP Siu KM Ma, Osteoporos Int 2008 19 357 364 10.1007/s00198-007-0505-y 18038273
11. Zoledronic acid and clinical fractures and mortality after hip fracture. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen, N Engl J Med 2007 357 1799 1809 10.1056/NEJMoa074941 17878149
12. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. R Rizzoli N Burlet D Cahall PD Delmas EF Eriksen D Felsenberg J Grbic M Jontell R Landesberg A Laslop M Wollenhaupt S Papapoulos O Sezer M Sprafka JY Reginster, Bone 2008 42 841 847 10.1016/j.bone.2008.01.003 18314405
13. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. N Yarom R Yahalom Y Shoshani W Hamed E Regev S Elad, Osteoporos Int 2007 18 1363 1370 10.1007/s00198-007-0384-2 17598065
14. Hepatotoxicity induced by alendronate therapy. B Yanik C Turkay H Atalar, Osteoporos Int 2007 18 829 831 10.1007/s00198-007-0323-2 17226065
15. Alendronate-induced auditory hallucinations and visual disturbances. CI Coleman KA Perkerson A Lewis, Pharmacotherapy 2004 24 799 802 10.1592/phco.24.8.799.36062 15222671
16. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos CL Ping Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings, N Engl J Med 2007 356 1809 1822 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
17. Alendronate and atrial fibrillation 25. SR Cummings AV Schwartz DM Black, N Engl J Med 2007 356 1895 1896 10.1056/NEJMc076132 17476024
18. Yearly zoledronic acid in postmenopausal osteoporosis 3. R Karam J Camm M McClung, N Engl J Med 2007 357 712 713 17703529
19. Use of alendronate and risk of incident atrial fibrillation in women. SR Heckbert G Li SR Cummings NL Smith BM Psaty, Arch Intern Med 2008 168 826 831 10.1001/archinte.168.8.826 18443257
20. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based case-control study. HT Sorensen S Christensen F Mehnert L Pedersen RD Chapurlat SR Cummings JA Baron, BMJ 2008 336 813 816 10.1136/bmj.39507.551644.BE 18334527
21. Atrial fibrillation in fracture patients treated with oral bisphosphonates. B Abrahamsen P Eiken K Brixen, J Intern Med 2009 265 581 592 10.1111/j.1365-2796.2008.02065.x 19141097
22. Meta-analysis: Principles and procedures. M Egger GD Smith AN Phillips, BMJ 1997 315 1533 1537 9432252
23. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? AR Jadad RA Moore D Carroll C Jenkinson DJM Reynolds DJ Gavaghan HJ McQuay, Control Clin Trials 1996 17 1 12 10.1016/0197-2456(95)00134- 4 8721797
24. Bayesian methods in meta-analysis and evidence synthesis. AJ Sutton KR Abrams, Stat Methods Med Res 2001 10 277 303 10.1191/096228001678227794 11491414
25. Multiparameter evidence synthesis in epidemiology and medical decision-making. AE Ades AJ Sutton, J R Statist Soc A 2006 169 5 35 10.1111/j.1467-985X.2005.00377.x
26. WinBUGS user manual: version 1.4. DJ Spiegelhalter A Thomas NG Best D Lunn, Cambridge (UK): MRC Biostatistics Unit 2001
27. R: A language and environment for statistical computing. R Development Core Team, 2009 http://www.r-project.org
28. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. D Moher DJ Cook S Eastwood I Olkin D Rennie DF Stroup, Lancet 1999 354 1896 1900 10.1016/S0140-6736(99)04149-5 10584742
29. Meta-analysis of observational studies in epidemiology: A proposal for reporting. DF Stroup JA Berlin SC Morton I Olkin GD Williamson D Rennie D Moher BJ Becker TA Sipe SB Thacker, JAMA 2000 283 2008 2012 10.1001/jama.283.15.2008 10789670
30. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud, Lancet 1996 348 1535 1541 10.1016/S0140-6736(96) 07088-2 8950879
31. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace A John Yates AZ Lacroix, JAMA 1998 280 2077 2082 10.1001/jama.280.24.2077 9875874
32. Ibandronate is not associated with an increased risk of atrial fibrillation; an assessment of annual cumulative exposure. S Papapoulous L Thompson F Hartl, Ann Rheum Dis 2008 67 Suppl II 538
33. Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE. CH Chesnut MP Ettinger PD Miller DJ Baylink R Emkey ST Harris RD Wasnich NB Watts RC Schimmer RR Recker, Curr Med Res Opin 2005 21 391 401 10.1185/030079905X30752 15811208
34. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. R Recker JA Stakkestad CH Chesnut Iii C Christiansen A Skag A Hoiseth M Ettinger P Mahoney RC Schimmer PD Delmas, Bone 2004 34 890 899 10.1016/j.bone.2004.01.008 15121021
35. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 Year results from the MOBILE study. JY Reginster S Adami P Lakatos M Greenwald JJ Stepan SL Silverman C Christiansen L Rowell N Mairon B Bonvoisin MK Drezner R Emkey D Felsenberg C Cooper PD Delmas PD Miller, Ann Rheum Dis 2006 65 654 661 10.1136/ard.2005.044958 16339289
36. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-Year results from the DIVA study. JA Eisman R Civitelli S Adami E Czerwinski C Recknor R Prince JY Reginster M Zaidi D Felsenberg C Hughes N Mairon D Masanauskaite DM Reid PD Delmas RR Recker, J Rheumatol 2008 35 488 497 18260172
37. Molecular basis of electrical remodeling in atrial fibrillation. DR Van Wagoner JM Nerbonne, J Mol Cell Cardiol 2000 32 1101 1117 10.1006/jmcc.2000.1147 10888261
38. The bisphosphonate acute phase response: Rapid and copious production of proinflammatory cytokines by peripheral blood T cells in response to aminobisphosphonates is inhibited by statins. RE Hewitt A Lissina AE Green ES Slay DA Price AK Sewell, Clin Exp Immunol 2005 139 101 111 10.1111/j.1365-2249. 2005.02665.x 15606619
39. Inflammation as a Risk Factor for Atrial Fibrillation. RJ Aviles DO Martin C Apperson-Hansen PL Houghtaling P Rautaharju RA Kronmal RP Tracy DR Van Wagoner BM Psaty MS Lauer MK Chung, Circulation 2003 108 3006 3010 10.1161/01.CIR.0000103131.70301.4F 14623805
40. Early Communication of an Ongoing Safety Review. FDA, http://www.fda.gov/Cder/Drug Assessed on 16th May 2009